Signaturefd LLC Acquires 306 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Signaturefd LLC raised its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 63.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 792 shares of the company’s stock after acquiring an additional 306 shares during the quarter. Signaturefd LLC’s holdings in Twist Bioscience were worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of TWST. American International Group Inc. raised its stake in Twist Bioscience by 0.8% during the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after acquiring an additional 213 shares during the period. Caprock Group LLC raised its position in shares of Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after purchasing an additional 220 shares during the period. Arizona State Retirement System lifted its stake in shares of Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after buying an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after buying an additional 312 shares in the last quarter. Finally, CWM LLC boosted its holdings in Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after buying an additional 524 shares during the period.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $43.18 on Thursday. The stock has a 50 day moving average price of $43.79 and a 200-day moving average price of $44.95. Twist Bioscience Co. has a one year low of $15.11 and a one year high of $60.90. The company has a market capitalization of $2.51 billion, a P/E ratio of -12.85 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The business had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The firm’s quarterly revenue was up 27.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.01) earnings per share. As a group, equities analysts predict that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on TWST shares. The Goldman Sachs Group boosted their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird upped their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Evercore ISI upped their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.22.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, COO Patrick John Finn sold 2,885 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $115,198.05. Following the transaction, the chief operating officer now owns 168,327 shares in the company, valued at $6,721,297.11. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Twist Bioscience news, COO Patrick John Finn sold 2,885 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $115,198.05. Following the completion of the transaction, the chief operating officer now owns 168,327 shares in the company, valued at $6,721,297.11. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Laponis sold 856 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the sale, the chief financial officer now directly owns 73,397 shares of the company’s stock, valued at $3,068,728.57. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,300 shares of company stock worth $1,801,822. 3.92% of the stock is currently owned by company insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.